Drug General Information
Drug ID	D08XOY
Former ID	DNCL001952
Drug Name	ABT-126
Indication	Mild to moderate alzheimer disease; Schizophrenia [ICD9: 331, 295; ICD10:G30, F20]		Phase 2	[524000]
Company	Abbott Laboratories
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Neuronal acetylcholine receptor protein, alpha-7 chain	Target Info	Modulator	[551664]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Cholinergic synapse
	Nicotine addiction
	Chemical carcinogenesis
PANTHER Pathway	Alzheimer disease-amyloid secretase pathway
	Nicotinic acetylcholine receptor signaling pathway
Reactome	Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
WikiPathways	SIDS Susceptibility Pathways
	Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
References
Ref 524000	ClinicalTrials.gov (NCT01655680) A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia. U.S. National Institutes of Health.
Ref 551664	A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.